"This is the first time that anyone has shown that it is possible to prevent a cardiac genetic disease in the long term, using gene therapy. After giving these mice the gene therapeutic product, one day after birth, the disease phenotype was prevented in the long term; eight months later, there was no sign of cardiac hypertrophy or dysfunction in the animals."
Lucie Carrier, professor of functional genomics of cardiomyopathies, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, discussing research findings published in the Dec. 2, 2014, edition of Nature Communications

"There is a strong and growing interest in the biopharma industry and the medical world to broaden the application of cancer immunotherapy to additional cancer types and patient populations through additional immune modulation approaches. Therefore, we are pleased by this experimental validation of our ability to discover additional types of immunomodulatory proteins to serve as target candidates for cancer immunotherapy, utilizing a completely different predictive methodology from the one we have successfully employed for the discovery to date of 11 B7/CD28-like proteins."
Anat Cohen-Dayag, president and CEO of Compugen Ltd., on successful initial experimental results for an immune checkpoint candidate predicted in silico utilizing a methodology designed to discover immunomodulators distinct from B7/CD28-like proteins

"Gene therapy, cell therapy and CAR-Ts are leading the front edge of engineered cells to treat diseases. It's a brave new world."
Barry Springer, vice president of technology, strategy and external innovation at the Janssen Biotechnology Center of Excellence, discussing the global CAR-T deal with Transposagen Biopharmaceuticals Inc.